



ASX ANNOUNCEMENT

13 July 2010

Excellent Additional VitroGro® Clinical Results & Completion of Commercial Scale Manufacturing

Biomedical company, **Tissue Therapies Limited (ASX: TIS)** has announced additional excellent human results from the Australian clinical trial of VitroGro® for the treatment of chronic venous ulcers as well as the successful completion of commercial scale Good Manufacturing Practice (GMP) production of VitroGro®.

A total of 22 chronic venous ulcer patients have now been treated with VitroGro® for 24 days each in the Australian clinical trial under the supervision of Professor Michael Stacey. Statistical analysis of the results was performed by staff from the University of Western Australia.

Some of the exceptional results from this 24-day human venous ulcer trial include:

- Complete healing of 4 ulcers out of 22
- Average reduction of ulcer area of 40% in 24 days
- Statistical significance of $p < 0.0001$

In this human trial:

- Average age of patients was 68 years
- Average duration of the venous ulcer prior to VitroGro® treatment was 13 months
- Average duration of compression therapy (the current gold standard of care) prior to joining the VitroGro® trial was 12 months

These clinical results are in addition to the exceptional results achieved in the already announced Canadian human trial of 10 patients all of whom were extremely medically challenging and were in the most difficult hard-to-heal category. (Please see ASX: TIS CEO AGM Presentation 27 November 2009.)

The CEO of Tissue Therapies, Dr Steven Mercer has also confirmed that commercial scale manufacturing of VitroGro® to GMP standards is complete and that the EU clinical trial of VitroGro® will start shortly and finish as planned by the end of calendar 2010.

Further information:

Dr Steven Mercer
CEO, Tissue Therapies Limited
Telephone: +61 (0)7 3839 9938

Email: s.mercer@tissuetherapies.com

About Tissue Therapies Limited

Tissue Therapies Limited is an Australian company developing biomedical technologies for wound healing, tissue repair and cell culture applications.

The Company has worldwide exclusive rights to commercialise VitroGro®, a technology developed by tissue engineering experts at the Institute of Health and Biomedical Innovation at QUT for enhancing cell growth and migration. VitroGro® has particular commercial applications in wound healing, tissue regeneration, stem cell therapies and other cell culture uses.

Based on its VitroGro® technology, Tissue Therapies is developing more effective medical treatments for wound healing including chronic skin ulcers and burns.

Tissue Therapies also provides cell culture reagents to enhance the growth of mammalian cells for emerging cell-based therapies, along with research and industrial cell culture markets internationally.

More information: www.tissuetherapies.com